Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nektar Therapeutics - Common Stock (NQ:NKTR)

73.69 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,749
Open 73.69
Bid (Size) 73.80 (100)
Ask (Size) 75.00 (200)
Prev. Close 73.69
Today's Range 73.69 - 73.69
52wk Range 26.45 - 109.00
Shares Outstanding 183,801,441
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Nektar (NKTR) Q2 2026 Earnings Call Transcript ↗
Phase 3 trials for rezpegaldesleukin advance in atopic dermatitis and alopecia areata. 
Via The Motley Fool
Topics Earnings
News headline image
Nektar Therapeutics Q2 Earnings Call Highlights ↗
Nektar Therapeutics (NASDAQ:NKTR) said it initiated its global Phase III ZENITH AD program for rezpegaldesleukin, or REZPEG, in moderate-to-severe atopic dermatitis during July, while also finalizing... 
Via MarketBeat
Topics Earnings

Performance

YTD
+69.7%
+69.7%
1 Month
+3.3%
+3.3%
3 Month
+12.4%
+12.4%
6 Month
+0.1%
+0.1%
1 Year
+171.5%
+171.5%

More News

Read More
News headline image
Full Transcript: Nektar Therapeutics Q2 2026 Earnings Call ↗
Via Benzinga
NEKTAR THERAPEUTICS (NASDAQ:NKTR) Q1 Earnings Beat Revenue Estimates but EPS Miss Drags Stock Lower ↗
Via Chartmill
Topics Earnings
News headline image
What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch ↗
Via The Motley Fool
News headline image
This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34% ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗
Via The Motley Fool
News headline image
Nektar Therapeutics Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Nektar (NKTR) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers – NKTR
From Pomerantz LLP
Via GlobeNewswire
News headline image
NEKTAR THERAPEUTICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm Before May 5th
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Deadline Soon: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
NKTR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTR
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT - Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers – NKTR
From Pomerantz LLP
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
NEKTAR THERAPEUTICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
NKTR Deadline: Rosen Law Firm Urges Nektar Therapeutics (NASDAQ: NKTR) Stockholders to Contact the Firm for Information About Their Rights
From Rosen Law Firm
Via Business Wire
News headline image
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Nektar Therapeutics Class Action Reminder – Robbins LLP Encourages NKTR Investors to Contact the Firm for Information About Their Rights
From Robbins LLP
Via Business Wire
News headline image
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces a Securities Class Action Lawsuit Filed Against Nektar Therapeutics (NKTR)
From Bernstein Liebhard LLP
Via GlobeNewswire

Frequently Asked Questions

Is Nektar Therapeutics - Common Stock publicly traded?
Yes, Nektar Therapeutics - Common Stock is publicly traded.
What exchange does Nektar Therapeutics - Common Stock trade on?
Nektar Therapeutics - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Nektar Therapeutics - Common Stock?
The ticker symbol for Nektar Therapeutics - Common Stock is NKTR on the Nasdaq Stock Market
What is the current price of Nektar Therapeutics - Common Stock?
The current price of Nektar Therapeutics - Common Stock is 73.69
When was Nektar Therapeutics - Common Stock last traded?
The last trade of Nektar Therapeutics - Common Stock was at 08/24/26 04:00 PM ET
What is the market capitalization of Nektar Therapeutics - Common Stock?
The market capitalization of Nektar Therapeutics - Common Stock is 13.54B
How many shares of Nektar Therapeutics - Common Stock are outstanding?
Nektar Therapeutics - Common Stock has 14B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.